When the next patient asks me about a game-changing HIV prevention tool, I hope I can say, “It’s already here and available to everyone who needs it.” ...

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Mark S. King’s January 10 blog post on his award-winning "My Fabulous Disease" site made me aware of a new, and troubling, ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicinesDAVOS/GENEVA, ...

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter. HB-500 ...

Cognizant and Gilead expand partnership to drive greater value through advanced technology applications: Teaneck, New Jersey Friday, January 31, 2025, 14:00 Hrs [IST] Cognizant ha ...

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...